Novavax files for authorization of COVID-19 shot among adolescents in Britain

Novavax Inc said on Wednesday it had filed an application with Britain's drugs regulator for the authorization of its COVID-19 vaccine among adolescents aged 12 and older. Britain had in February cleared the two-dose vaccine, Nuvaxovid, for use in adults amid a spike in cases fueled by the Omicron variant of the coronavirus. Novavax's submission includes data from a late-stage trial in the United States, where the vaccine showed 80% efficacy among adolescents when Delta was the dominant variant in the country.